Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating that there was insufficient information about its chemistry, manufacturing, and controls [2]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4].

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1] Group 1: Allegations and Impact - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2] - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2] - The public statements made by the defendants were materially false and misleading throughout the relevant period, impacting investor decisions [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit due to alleged misleading statements related to the approval of MOLBREEVI BLA, a treatment for pulmonary alveolar proteinosis [1][2]. Summary by Sections Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding MOLBREEVI BLA, including: - Lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls [1] - Unlikelihood of FDA approval for MOLBREEVI BLA in its current form [1] - Delay in submission of MOLBREEVI BLA within the previously represented timeframe [1] - Increased likelihood of needing to raise additional capital due to regulatory approval delays [1] - Overall, public statements made by the defendants were materially false and misleading [1]. Next Steps for Shareholders - Shareholders who purchased shares of SVRA during the specified timeframe are encouraged to register for the class action by November 7, 2025, to potentially become lead plaintiffs [2]. - Registration includes enrollment in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for failing to disclose critical information regarding the MOLBREEVI Biologics License Application, leading to significant investor losses [8]. Allegation Details - The lawsuit claims that during the class period from March 7, 2024, to May 23, 2025, Savara did not disclose that the MOLBREEVI BLA lacked sufficient information on chemistry, manufacturing, and controls, making FDA approval unlikely [8]. - The complaint also states that the delay in regulatory approval would likely necessitate Savara to raise additional capital [8]. - Following the announcement of a refusal to file letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [8]. Next Steps - Investors who purchased Savara shares during the class period and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4].

Core Viewpoint - A class action has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during a specified period [1][3]. Group 1: Allegations - The complaint states that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient data on chemistry, manufacturing, and controls [3]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay the submission timeline previously communicated to investors [3]. - The delay in regulatory approval raised concerns about the company's need to raise additional capital [3]. Group 2: Impact on Stock Price - Following the announcement of a refusal to file (RTF) letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share on May 27, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by November 7, 2025 [5]. - Shareholders can remain absent class members if they choose not to participate in the case [5].

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for treating pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2] - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

Core Viewpoint - Savara Inc. has announced the promotion of Dr. Yasmine Wasfi to Chief Medical Officer (CMO), effective immediately, succeeding Dr. Ray Pratt who will become Senior Medical Advisor [1] Company Summary - Savara Inc. is a clinical stage biopharmaceutical company focused on rare respiratory diseases [1] - Dr. Wasfi will report directly to the Company's Chair and Chief Executive Officer and will be part of the executive leadership team [1]

Core Viewpoint - Savara Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its drug MOLBREEVI, which is intended for the treatment of pulmonary alveolar proteinosis [3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from March 4, 2024, to May 23, 2025 [3]. - Allegations include that Savara failed to disclose critical information about MOLBREEVI's chemistry, manufacturing, and controls, leading to doubts about FDA approval [3]. - The lawsuit claims that the delay in regulatory approval would likely necessitate Savara to raise additional capital [3]. Group 2: Shareholder Actions - Shareholders who purchased SVRA shares during the class period are encouraged to register for the class action, with a deadline of November 7, 2025, to seek lead plaintiff status [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [4]. Group 3: Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for protecting investors' rights against deceit and fraud [5]. - The firm emphasizes its commitment to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - Savara Inc. is facing a class action lawsuit due to alleged securities fraud following the FDA's refusal to file letter regarding its MOLBREEVI BLA, which led to a significant drop in share price [3][4]. Group 1: Company Announcement - On May 27, 2025, Savara announced that it received a refusal to file letter from the FDA for the MOLBREEVI BLA, indicating that the submission was not sufficiently complete for review [3]. - Following this announcement, Savara's share price fell by $0.90, or approximately 31.69%, from $2.84 on May 23, 2025, to $1.94 on May 27, 2025 [3]. Group 2: Lawsuit Details - The lawsuit is on behalf of investors who purchased securities between March 7, 2024, and May 23, 2025, alleging that Savara made false or misleading statements regarding the MOLBREEVI BLA [4]. - Specific allegations include that the MOLBREEVI BLA lacked sufficient information on chemistry, manufacturing, and controls, making FDA approval unlikely in its current form [4]. - The lawsuit also claims that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities during the specified class period of the upcoming lead plaintiff deadline on November 7, 2025, and the potential for compensation through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought Savara securities between March 7, 2024, and May 23, 2025, may be eligible for compensation without upfront costs [1]. - A class action lawsuit has already been filed, and interested parties must act by the November 7, 2025 deadline to serve as lead plaintiff [2]. - The lawsuit alleges that Savara made false or misleading statements regarding the approval process of its drug MOLBREEVI, impacting investor decisions [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of settlements since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3].